## —Images and Videos—

## An unexpected complication during EUS-FNA

### Khaled Ragab<sup>1</sup>, Ahmed Mohammed Elmeligui<sup>2</sup>, Hassan Atalla<sup>3</sup>, Hussein Hassan Okasha<sup>4</sup>

<sup>1</sup>Division of Gastroenterology, Hepatology and Endoscopy, Theodor Bilharz Research Institute, Giza, Egypt; <sup>2</sup>Division of Gastroenterology, Hepatology and Endoscopy, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt; <sup>3</sup>Department of Internal Medicine, Hepatology and Gastroenterology Unit, Faculty of Medicine, Mansoura University, Mansoura, Egypt; <sup>4</sup>Department of Internal Medicine, Division of Gastroenterology, Hepatology and Endoscopy, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt

A 73-year-old diabetic and hypertensive male patient presented with progressive dysphagia and marked weight loss. There is no intake of antiplatelets or anticoagulants. Upper endoscopy revealed distal esophageal stricture with inconclusive biopsy results, so he was referred for EUS evaluation.

First, a linear echoendoscope was advanced into the distal esophagus where a short esophageal stricture was encountered at 33 cm from the incisors. There was an esophageal wall circumferential hypovascular mass in the

Hypoechoic lesion arising from esophageal walk with loss of five-layer differentiation

**Figure 1.** A soft tissue lesion is infiltrating the distal esophageal wall with loss of wall layer structure



most distal 4 cm with loss of wall layer differentiation, raising the possibility of a malignant neoplasm [Figure 1]. EUS-FNA was done using a 22G needle (EchoTip, Wilson-Cook) by conventional tissue actuation method with the aid of stylet and suction [Figure 2]. Instantaneous bleeding inside the lesion was evident endosonographically by observing a dense turbid fluid collection within the lesion [Figure 3] and endoscopically by further narrowing of the lumen as a result of newly formed hematoma [Figure 4]. A forward-viewing endoscopy was then



Figure 2. EUS-FNA of the distal esophageal wall lesion

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow\_reprints@wolterskluwer.com


**How to cite this article:** Ragab K, Elmeligui AM, Atalla H, Okasha HH. An unexpected complication during EUS-FNA. Endosc Ultrasound 2022;11:145-6.

#### Address for correspondence

Prof. Hussein Hassan Okasha, Division of Gastroenterology, Hepatology and Endoscopy, Kasr Al-Ainy School of Medicine, Cairo University, Egypt.

E-mail: okasha\_hussein@hotmail.com

Received: 2021-01-09; Accepted: 2021-05-06; Published online: 2021-09-03



**Figure 3.** Post-EUS-FNA wall hematoma as seen by EUS (left panel). Post-EUS-FNA wall hematoma (another view, right panel)



**Figure 5.** The proximal end of the first deployed self-expandable metal stents

introduced, and a Savary guidewire was passed through the narrowed lumen. An 11 cm/18 mm partially covered metal stent (self-expandable metal stents) was deployed at the site of stricture [Figure 5], and then, a second similar one was inserted proximal to the first one (stent-in-stent technique) with its proximal end above the upper level of the hematoma to act as a hemostatic scaffold and to dilate the partially obstructed lumen by the hematoma [Figure 6]. Follow-up period after the procedure was uneventful and the patient was discharged after 2 days. Cytopathological analysis revealed esophageal adenocarcinoma.

EUS-FNA is an established standard method for tissue acquisition from different gastrointestinal tumors and strictures. Reported overall adverse event from EUS-FNA was 0.98% that included a bleeding rate of 0.13% in recent meta-analysis. EUS-FNA is considered a high-risk procedure according to the guidelines of the European and American Society of Gastrointestinal Endoscopy, especially in patients taking antithrombotic agents which should be stopped before the procedure. However, bleeding is still possible even after these drugs had been stopped. Although very uncommon, we have demonstrated that bleeding is a potential adverse event of EUS-FNA and attention should be taken during and after this procedure.

### Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given his consent for his images and other clinical information to be reported in the journal. The



Figure 4. Post-EUS-FNA wall hematoma as seen by upper endoscopy



**Figure 6.** The proximal end of the second deployed self-expandable metal stents

patient understands that his names and initials will not be published and due efforts will be made to conceal his identity, but anonymity cannot be guaranteed.

# Financial support and sponsorship Nil.

#### Conflicts of interest

Hussein Hassan Okasha is an Editorial Board Member of the journal. The article was subject to the journal's standard procedures, with peer review handled independently of this Member and his research groups.

#### **REFERENCES**

- Wang KX, Ben QW, Jin ZD, et al. Assessment of morbidity and mortality associated with EUS-guided FNA: A systematic review. Gastrointest Endosc 2011;73:283-90.
- Veitch AM, Vanbiervliet G, Gershlick AH, et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Endoscopy 2016;48:385-402.
- ASGE Standards of Practice Committee; Acosta RD, Abraham NS, et al.
   The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc 2016;83:3-16.
- Kawakubo K, Yane K, Eto K, et al. A prospective multicenter study evaluating bleeding risk after endoscopic ultrasound-guided fine needle aspiration in patients prescribed antithrombotic agents. Gut Liver 2018;12:353-9.